DrugPatentWatch Database Preview
KRINTAFEL Drug Profile
Which patents cover Krintafel, and when can generic versions of Krintafel launch?
Krintafel is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in KRINTAFEL is tafenoquine succinate. One supplier is listed for this compound. Additional details are available on the tafenoquine succinate profile page.
US Patents and Regulatory Information for KRINTAFEL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | KRINTAFEL | tafenoquine succinate | TABLET;ORAL | 210795-001 | Jul 20, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Glaxosmithkline | KRINTAFEL | tafenoquine succinate | TABLET;ORAL | 210795-001 | Jul 20, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
